ArticleFrontiers in oncology2026
GATA3-positivity and T follicular helper phenotype in transformed mycosis fungoides with leukemic involvement and prominent folliculotropism: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycosis fungoides (MF) shows a broad clinical spectrum, ranging from indolent disease to aggressive variants with poor outcomes. T Follicular Helper (TFH) marker expression has been reported in a subset of MF, with uncertain prognostic significance, while GATA3 has emerged as a potential adverse prognostic marker in MF and nodal T-cell lymphomas. Herein, we report a case of MF investigated through sequential histopathological and phenotypic analyses, including extended TFH markers and GATA3 immunohistochemistry. Initially diagnosed as conventional MF, the disease evolved after 3 years into MF with large cell transformation and leukemic involvement, characterized by prominent folliculotropism, a TFH phenotype, and diffuse GATA3 expression. Retrospective analysis of the initial biopsy identified a minor TFH/GATA3-positive neoplastic population (10%) already present at onset, supporting a model of progressive phenotypic plasticity evolving over time. This case underscores the biological heterogeneity of MF, suggesting that a TFH phenotype and GATA3 expression may help identify patients with a more aggressive disease course, potentially amenable to mogamulizumab-based targeted immunotherapy. Incorporating extended TFH markers and GATA3 into routine immunohistochemical assessment could refine risk stratification and inform treatment decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.